Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Head and Neck Cancer

Free Subscription Articles published in J Clin Endocrinol Metab Retrieve available abstracts of 172 articles: HTML format

Single Articles

October 2026
1. YANG L, Qian K, Huang Z, Guo K, et al
   Clinical and Molecular Genetic Testing Risk Stratification for Pediatric Papillary Thyroid Carcinoma Therapy.
   J Clin Endocrinol Metab. 2026 Oct 10:dgag418. doi: 10.1210.
   PubMed     Abstract available
   
   
   July 2026
2. SRIDHAR A, Behairy N, Klubo-Gwiezdzinska J
   Application of Theranostics in Thyroid Cancer Management.
   J Clin Endocrinol Metab. 2026 Jul 31:dgag310. doi: 10.1210.
   PubMed     Abstract available
   
   
   
3. MATRONE A, Gambale C, Prete A, Romei C, et al
   Impairment in the hypothalamic-pituitary-gonadal axis in males with medullary thyroid carcinoma treated with selpercatinib.
   J Clin Endocrinol Metab. 2026 Jul 23:dgag296. doi: 10.1210.
   PubMed     Abstract available
   
   
   
4. SONG JX, Yang YY, Zhou JX, Xie J, et al
   Parathyroid Carcinoma: From Molecular Pathogenesis to Multidisciplinary Management.
   J Clin Endocrinol Metab. 2026 Jul 4:dgag266. doi: 10.1210.
   PubMed     Abstract available
   
   
   June 2026
5. PITT S, Haymart MR
   Approach to the Patient with Low-Risk Thyroid Cancer.
   J Clin Endocrinol Metab. 2026 Jun 24:dgag243. doi: 10.1210.
   PubMed     Abstract available
   
   
   May 2026
6. LI XL, Chen LY, Shi KY, Fan PL, et al
   US-guided Nanosecond Pulsed Electric Field Ablation of Low-risk PTMC: Interim Results of a Prospective Multicenter Study.
   J Clin Endocrinol Metab. 2026;111:1596-1603.
   PubMed     Abstract available
   
   
   
7. KUMARI P, Bhadada SK, Arya AK, Kaur J, et al
   Aberrant Histone Methylation Profile in Patients with Sporadic Primary Hyperparathyroidism.
   J Clin Endocrinol Metab. 2026;111:1680-1691.
   PubMed     Abstract available
   
   
   April 2026
8. LARIOS F, Borras-Osorio M, Wu Y, Claros AG, et al
   Artificial Intelligence-Enabled Analysis of Radiology Reports: Epidemiology and Outcomes of Incidental Thyroid Findings.
   J Clin Endocrinol Metab. 2026 Apr 27:dgag186. doi: 10.1210.
   PubMed     Abstract available
   
   
   
9. WASSERMAN JD, Isaza AR, Waguespack SG, Wassner AJ, et al
   The Landscape of Pediatric Differentiated Thyroid Carcinoma and Predictors of Invasive Disease: A CATC Study.
   J Clin Endocrinol Metab. 2026 Apr 22:dgag172. doi: 10.1210.
   PubMed     Abstract available
   
   
   
10. GRAF KE, Adam P, Megerle F, Machlah YM, et al
    Outcome Of First-Line Chemotherapy For Anaplastic Thyroid Cancer - A Multicenter Registry Analysis.
    J Clin Endocrinol Metab. 2026 Apr 21:dgag177. doi: 10.1210.
    PubMed     Abstract available
    
    
    
11. MONETA C, Trevisan M, Colombo C, De Luca A, et al
    VALIDATION OF THE 2025 ATA RISK STRATIFICATION SYSTEM IN A COHORT OF PATIENTS WITH PAPILLARY THYROID CARCINOMA.
    J Clin Endocrinol Metab. 2026 Apr 17:dgag167. doi: 10.1210.
    PubMed     Abstract available
    
    
    March 2026
12. MINALDI E, Ramone T, Ciampi R, Romei C, et al
    Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment.
    J Clin Endocrinol Metab. 2026 Mar 27:dgag074. doi: 10.1210.
    PubMed     Abstract available
    
    
    February 2026
13. FLACHS MADSEN LR, Kesmodel US, Kragelund Nielsen K, Damm P, et al
    Gestational diabetes mellitus and risk of selected cancers: a Danish national register-based cohort study.
    J Clin Endocrinol Metab. 2026 Feb 25:dgag068. doi: 10.1210.
    PubMed     Abstract available
    
    
    
14. CANBERK S, Baloch ZW, Isaza A, Bojarsky M, et al
    Age-Specific Risk of Malignancy in Pediatric Thyroid Cytology: Reframing ROM based on pre-test probability.
    J Clin Endocrinol Metab. 2026 Feb 25:dgag073. doi: 10.1210.
    PubMed     Abstract available
    
    
    
15. PATRIZIO A, Mauguen A, Fagin JA, Farooki A, et al
    Exposure to GLP-1RA and risk of structural progression in differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2026 Feb 15:dgag051. doi: 10.1210.
    PubMed     Abstract available
    
    
    
16. PRETE A, Matrone A, Romei C, Gambale C, et al
    Calcitonin Thresholds for Prediction of Medullary Thyroid Carcinoma and its Clinical Response in MEN2A Gene Carriers.
    J Clin Endocrinol Metab. 2026 Feb 14:dgag041. doi: 10.1210.
    PubMed     Abstract available
    
    
    
17. CASTELLANOS LE, Bryan J, Ricarte-Filho JC, Franco AT, et al
    Afirma Genomic Sequencing Classifier Performance in Young Patients with Cytologically Indeterminate Thyroid Nodules.
    J Clin Endocrinol Metab. 2026 Feb 12:dgag059. doi: 10.1210.
    PubMed     Abstract available
    
    
    
18. AHMADI S, Kotwal A, Bikas A, Altshuler BF, et al
    Utility of Genomic Sequencing Classifier in Managing Cytologically Indeterminate Oncocytic Thyroid Nodules.
    J Clin Endocrinol Metab. 2026 Feb 6:dgag044. doi: 10.1210.
    PubMed     Abstract available
    
    
    January 2026
19. FINNEGAN EA, Ganly I
    Approach to the Patient: Oncocytic Thyroid Cancer.
    J Clin Endocrinol Metab. 2026 Jan 28:dgag025. doi: 10.1210.
    PubMed     Abstract available
    
    
    December 2025
20. MACHLAH YM, Brandenburg T, Muchalla P, Tiedje V, et al
    Comprehensive Assessment of Multikinase Inhibitor Therapy Outcomes in RAIR-(P)DTC and MTC at a Tertiary Referral Center.
    J Clin Endocrinol Metab. 2025;111:167-179.
    PubMed     Abstract available
    
    
    
21. ANGELOPOULOS N, Goulis DG, Chrisogonidis I, Iakovou I, et al
    Elastography enhances diagnostic accuracy of ACR TI-RADS in thyroid nodule evaluation.
    J Clin Endocrinol Metab. 2025 Dec 18:dgaf670. doi: 10.1210.
    PubMed     Abstract available
    
    
    
22. WANG Z, Yang S, Li Y, Tian J, et al
    An Interpretable Machine Learning Model for Predicting Occult Central Lymph Node Metastasis in Papillary Thyroid Cancer.
    J Clin Endocrinol Metab. 2025 Dec 11:dgaf636. doi: 10.1210.
    PubMed     Abstract available
    
    
    November 2025
23. DAN R, Paran N, Vinegrad N, Fraenkel M, et al
    Parity as a Risk Factor for Differentiated Thyroid Carcinoma- A Population-Based Study.
    J Clin Endocrinol Metab. 2025 Nov 24:dgaf642. doi: 10.1210.
    PubMed     Abstract available
    
    
    
24. GARZA B, Calhoun J, Norman P, Cline N, et al
    Tumor-infiltrating T Lymphocytes Recognize Thyroid-specific and Neo-antigens in Follicular Cell-derived Thyroid Cancers.
    J Clin Endocrinol Metab. 2025 Nov 22:dgaf639. doi: 10.1210.
    PubMed     Abstract available
    
    
    
25. LEE JS, Kim NK, Jeong HJ, Yun HJ, et al
    Impact of Subtype Variability on Clinical Features in Papillary Thyroid Cancer.
    J Clin Endocrinol Metab. 2025 Nov 19:dgaf531. doi: 10.1210.
    PubMed     Abstract available
    
    
    
26. SONG JX, Xie J, Zhou JX, Zhang YF, et al
    Approach to the Patient With Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1.
    J Clin Endocrinol Metab. 2025;110:3546-3558.
    PubMed     Abstract available
    
    
    
27. YU CY, Chu EH, Lin CH, Chen YC, et al
    Diagnostic Efficiency of Thyroglobulin in Lymph Node Fine-needle Aspiration Washout: A Systematic Review and Meta-analysis.
    J Clin Endocrinol Metab. 2025;110:3569-3587.
    PubMed     Abstract available
    
    
    
28. DEVOUGE AC, Lasolle H, Dupin C, Vergniol J, et al
    Outcomes and Therapeutic Strategies for Head-and-neck Paragangliomas Associated With Succinate Dehydrogenase Mutations.
    J Clin Endocrinol Metab. 2025;110:e4030-e4037.
    PubMed     Abstract available
    
    
    
29. SOTO JACOME C, Arce-Camposano A, Toro-Tobon D, Al Zahidy M, et al
    Drug Repurposing for Reducing the Size of Benign Thyroid Nodules: A Systematic Review.
    J Clin Endocrinol Metab. 2025 Nov 12:dgaf616. doi: 10.1210.
    PubMed     Abstract available
    
    
    
30. DOBNIG H, Amrein K
    Mid- to Long-term Outcomes After Single Radiofrequency Ablation of Non-Toxic and Toxic Thyroid Nodules.
    J Clin Endocrinol Metab. 2025 Nov 4:dgaf611. doi: 10.1210.
    PubMed     Abstract available
    
    
    October 2025
31. HABIB S, Perez Rodriguez Garcia G, Zhang Z, Roy A, et al
    Determining Thyroid Biopsy Appropriateness: A Retrospective Study Integrating Clinical Context and Ultrasound Features.
    J Clin Endocrinol Metab. 2025 Oct 24:dgaf577. doi: 10.1210.
    PubMed     Abstract available
    
    
    
32. GAMBELUNGHE G, Del Sindaco P, Morettini F, Ristagno S, et al
    Percutaneous Laser Ablation for Thyroid Nodules: Efficacy and Safety in 1,492 Patients with Median Follow-up >/= 10 Years.
    J Clin Endocrinol Metab. 2025 Oct 24:dgaf581. doi: 10.1210.
    PubMed     Abstract available
    
    
    
33. CASALINI R, Romei C, Bottici V, Cappagli V, et al
    Prevalence and genetics of "de novo" MEN2 syndromes.
    J Clin Endocrinol Metab. 2025;110:e3559-e3565.
    PubMed     Abstract available
    
    
    
34. NAKATANI R, Watabe T, Fukuhara A, Takano T, et al
    Initial evaluation of radioiodine therapy using Imaging for long-term prognosis in thyroid cancer: A retrospective study.
    J Clin Endocrinol Metab. 2025 Oct 15:dgaf568. doi: 10.1210.
    PubMed     Abstract available
    
    
    
35. RITTER A, Eagan A, Levyn H, Tuttle RM, et al
    Comparable Outcomes of Differentiated Thyroid Cancer in Immunocompromised versus Immunocompetent Patients.
    J Clin Endocrinol Metab. 2025 Oct 7:dgaf550. doi: 10.1210.
    PubMed     Abstract available
    
    
    September 2025
36. POZDEYEV N, White SL, Bell CC, Haugen BR, et al
    Artificial intelligence applications in thyroid cancer care.
    J Clin Endocrinol Metab. 2025 Sep 25:dgaf530. doi: 10.1210.
    PubMed     Abstract available
    
    
    
37. VALENCIAGA A, Liyanarachchi S, Brock PL, Ringel MD, et al
    Long-term outcomes of patients diagnosed with differentiated thyroid cancer in childhood and young adulthood.
    J Clin Endocrinol Metab. 2025 Sep 18:dgaf522. doi: 10.1210.
    PubMed     Abstract available
    
    
    
38. XU X, Zhang C, Wang G, Dong B, et al
    Correlation of TgAb With Clinicopathological Features and Unfavorable Efficacy of 131I Ablation in PTC.
    J Clin Endocrinol Metab. 2025;110:e3245-e3251.
    PubMed     Abstract available
    
    
    
39. REDLICH A, Pfaehler E, Kunstreich M, Schmutz M, et al
    ML Prediction of Recurrence in Pediatric Thyroid Cancer: MET Cohort Analysis Using XGBoost and SHAP.
    J Clin Endocrinol Metab. 2025 Sep 1:dgaf487. doi: 10.1210.
    PubMed     Abstract available
    
    
    August 2025
40. CHO YY, Ahn SH, Kim M, Lee EK, et al
    TSH Cut-Offs and Recurrence Risk in Differentiated Thyroid Carcinomas: A Systematic Review and Meta-Analysis.
    J Clin Endocrinol Metab. 2025 Aug 14:dgaf463. doi: 10.1210.
    PubMed     Abstract available
    
    
    
41. BILGIN C, Hibbert R, Oztepe F, Sfeir JG, et al
    Percutaneous Ablation of Parathyroid Adenomas: A Systematic Review and Meta-Analysis.
    J Clin Endocrinol Metab. 2025;110:e3150-e3162.
    PubMed     Abstract available
    
    
    July 2025
42. GREENSPUN BC, Metzger DA, Lee S, Pearson BE, et al
    Long Term Survivors of Anaplastic Thyroid Cancer: A Genomic Predictive Model.
    J Clin Endocrinol Metab. 2025 Jul 15:dgaf391. doi: 10.1210.
    PubMed     Abstract available
    
    
    
43. BODOQUE-CUBAS J, Fernandez-Saez J, Martinez-Hervas S, Perez-Lacasta MJ, et al
    Integrating Artificial Intelligence in Thyroid Nodule Management: Clinical Outcomes and Cost-Effectiveness Analysis.
    J Clin Endocrinol Metab. 2025 Jul 12:dgaf399. doi: 10.1210.
    PubMed     Abstract available
    
    
    June 2025
44. HAMIDI S, Maniakas A, Akhave NS, Banuchi VE, et al
    Characterization of advanced RAS-driven follicular-derived thyroid cancers and review of future therapeutic avenues.
    J Clin Endocrinol Metab. 2025 Jun 26:dgaf366. doi: 10.1210.
    PubMed     Abstract available
    
    
    
45. YAMAZAKI H, Sugino K, Katoh R, Matsuzu K, et al
    Clinical Significance of Successful Ablation in Follicular Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2025 Jun 4:dgaf326. doi: 10.1210.
    PubMed     Abstract available
    
    
    May 2025
46. NISHIKAWA Y, Oguro F, Suzuki C, Kobashi Y, et al
    Stable iodine intake and thyroid screening outcomes after the Fukushima Nuclear Disaster: an observational study.
    J Clin Endocrinol Metab. 2025 May 29:dgaf312. doi: 10.1210.
    PubMed     Abstract available
    
    
    
47. FRICH PS, Sigstad E, Berstad AE, Opsahl EM, et al
    Ethanol Ablation of Metastatic Lymph Nodes in Patients with Papillary Thyroid Carcinoma - Predictors of Clinical Outcome.
    J Clin Endocrinol Metab. 2025 May 23:dgaf298. doi: 10.1210.
    PubMed     Abstract available
    
    
    April 2025
48. WHITE SL, Jamil T, Bell C, Fishbein L, et al
    Population prevalence of the major thyroid cancer-associated syndromes.
    J Clin Endocrinol Metab. 2025 Apr 15:dgaf236. doi: 10.1210.
    PubMed     Abstract available
    
    
    
49. HIRUMA S, Watanabe N, Noh JY, Hirose R, et al
    Occurrence of Newly Diagnosed Thyroid Cancer Is Not Increased After Radioactive Iodine Therapy for Graves' Disease.
    J Clin Endocrinol Metab. 2025 Apr 11:dgaf231. doi: 10.1210.
    PubMed     Abstract available
    
    
    
50. KU EJ, Lee J, Yoo WS, Bae J, et al
    Long-Term Non-skeletal Complications in Patients with Thyroid Cancer and Hypoparathyroidism Post-total Thyroidectomy.
    J Clin Endocrinol Metab. 2025 Apr 2:dgaf213. doi: 10.1210.
    PubMed     Abstract available
    
    
    
51. DE LEO S, Brigante G, D'Elia S, Censi S, et al
    Prospective Validation of ATA Risk Score for Papillary Thyroid Microcarcinoma: An ITCO Real-World Study.
    J Clin Endocrinol Metab. 2025 Apr 1:dgaf190. doi: 10.1210.
    PubMed     Abstract available
    
    
    March 2025
52. SHARIQ OA, Waguespack SG, Hamidi S, Kensing BC, et al
    Approach to the Patient: Hereditary Medullary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2025 Mar 19:dgaf089. doi: 10.1210.
    PubMed     Abstract available
    
    
    
53. SIMONDS WF, Li Y, Jha S
    Genotype-Phenotype Correlations in the Hyperparathyroidism-Jaw Tumor Syndrome.
    J Clin Endocrinol Metab. 2025;110:931-939.
    PubMed     Abstract available
    
    
    
54. AEKKA A, Arva NC, Ren HZ, Raval M, et al
    Multiplatform Molecular Testing as an Adjunct to Fine Needle Aspiration in the Evaluation of Pediatric Thyroid Nodules.
    J Clin Endocrinol Metab. 2025 Mar 4:dgaf110. doi: 10.1210.
    PubMed     Abstract available
    
    
    February 2025
55. SCAPPATICCIO L, Di Martino N, Ferrazzano P, Maiorino MI, et al
    Prevalence and Management of Complications of Laser Ablation for Benign Thyroid Nodules: A Systematic Review of Literature and Meta-analysis.
    J Clin Endocrinol Metab. 2025 Feb 20:dgaf108. doi: 10.1210.
    PubMed     Abstract available
    
    
    
56. GOLDFARB M, Bustos MA, Moon J, Jackson K, et al
    Pilot Study of Plasma miRNA Signature Panel for Differentiating Single vs Multiglandular Parathyroid Disease.
    J Clin Endocrinol Metab. 2025;110:758-770.
    PubMed     Abstract available
    
    
    
57. LAI ST, Bauer AJ
    Approach to the Pediatric Patient with Thyroid Nodules.
    J Clin Endocrinol Metab. 2025 Feb 13:dgaf090. doi: 10.1210.
    PubMed     Abstract available
    
    
    
58. ZHOU J, Li D, Ren J, Huang C, et al
    Machine Learning: A Multicentre Study on Predicting Lateral Lymph Node Metastasis in cN0 Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2025 Feb 8:dgaf070. doi: 10.1210.
    PubMed     Abstract available
    
    
    
59. WANG L, Zhang L, Ma R, Zhang Y, et al
    Semaglutide reprograms macrophages via the GLP-1R/PPARG/ACSL1 pathway to suppress papillary thyroid carcinoma growth.
    J Clin Endocrinol Metab. 2025 Feb 5:dgaf053. doi: 10.1210.
    PubMed     Abstract available
    
    
    
60. CIRELLO V, Colombo C, Tosi D, Manzo A, et al
    TP53 Alterations Associate with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer.
    J Clin Endocrinol Metab. 2025 Feb 1:dgaf056. doi: 10.1210.
    PubMed     Abstract available
    
    
    January 2025
61. TELITI M, Chytiris S, Coperchini F, Cerutti M, et al
    The natural history of cytologically low-risk indeterminate thyroid nodules.
    J Clin Endocrinol Metab. 2025 Jan 29:dgaf052. doi: 10.1210.
    PubMed     Abstract available
    
    
    
62. VAN DER MEEREN MMD, Boers T, de Graaf P, Duvivier KM, et al
    Radiofrequency ablation for thyroid nodules (RATED study) - analysis of a learning curve and predictors of success.
    J Clin Endocrinol Metab. 2025 Jan 29:dgaf058. doi: 10.1210.
    PubMed     Abstract available
    
    
    
63. LI Y, Simonds WF, Chen H
    A Comparative Genomic Analysis of Parathyroid Adenomas and Carcinomas Harboring Heterozygous Germline CDC73 Mutations.
    J Clin Endocrinol Metab. 2025;110:429-440.
    PubMed     Abstract available
    
    
    
64. NAKAI T, Horiuchi K, Okamoto T
    Predicting Tumor Volume in Primary Hyperparathyroidism From Preoperative Clinical Data.
    J Clin Endocrinol Metab. 2025;110:e391-e396.
    PubMed     Abstract available
    
    
    
65. SONG JX, Dong YQ, Han RL, Xie J, et al
    PI3K/AKT/mTOR Activation is Associated with Malignant Severity and Poorer Prognosis in Parathyroid Carcinomas.
    J Clin Endocrinol Metab. 2025 Jan 20:dgaf042. doi: 10.1210.
    PubMed     Abstract available
    
    
    
66. ROBENSHTOK E, Bachar G, Ritter A
    Approach to the Patient with Thyroid Cancer: Selection and Management of Candidates for Lobectomy.
    J Clin Endocrinol Metab. 2025 Jan 2:dgae903. doi: 10.1210.
    PubMed     Abstract available
    
    
    November 2024
67. CHEN Z, Sun W, Fei M, Qian K, et al
    Clinical and Sonographic Differences between RET Fusion-Positive and BRAFV600E in Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2024 Nov 18:dgae803. doi: 10.1210.
    PubMed     Abstract available
    
    
    
68. SCHUMM MA, Nikiforov YE, Nikiforova MN, Wald AI, et al
    Association of BRAF V600E allele frequency with clinicopathologic outcomes in papillary thyroid cancer.
    J Clin Endocrinol Metab. 2024 Nov 14:dgae774. doi: 10.1210.
    PubMed     Abstract available
    
    
    
69. 
    Correction to: "Prognostic Analysis of 131I Efficacy After Papillary Thyroid Carcinoma Surgery Based on CT Radiomics".
    J Clin Endocrinol Metab. 2024 Nov 1:dgae756. doi: 10.1210.
    PubMed    
    
    
    October 2024
70. MENG L, Li H, Fu Y, Yu D, et al
    Somatic DICER1-Mutant Benign Thyroid Nodules in Adults: A Group of Follicular Nodular Disease With Continuous Growth.
    J Clin Endocrinol Metab. 2024 Oct 28:dgae750. doi: 10.1210.
    PubMed     Abstract available
    
    
    
71. PARVATHAREDDY SK, Siraj AK, Qadri Z, Siraj N, et al
    The Prognostic Impact of Tumor Size and BRAF Mutational Status in Middle Eastern Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Oct 18:dgae740. doi: 10.1210.
    PubMed     Abstract available
    
    
    
72. 
    Correction to: "Pediatric Papillary Thyroid Carcinoma: Outcomes After Surgery Without Adjuvant Radioactive Iodine".
    J Clin Endocrinol Metab. 2024 Oct 16:dgae717. doi: 10.1210.
    PubMed    
    
    
    
73. BEHAIRY N, Leonardi AJ, Gubbi S, Kumari S, et al
    Tumor Volume Doubling Time of Less Than One Year is Associated with a Higher Risk of Death from Medullary Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Oct 16:dgae733. doi: 10.1210.
    PubMed     Abstract available
    
    
    
74. KELLY CA, Sipos JA
    Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists.
    J Clin Endocrinol Metab. 2024 Oct 14:dgae722. doi: 10.1210.
    PubMed     Abstract available
    
    
    
75. LEE S, Antunez AG, Sinco B, Saucke MC, et al
    Cancer-related Fear and Worry in Patients with Low-Risk Thyroid Cancer: A Longitudinal Cohort Study.
    J Clin Endocrinol Metab. 2024 Oct 14:dgae688. doi: 10.1210.
    PubMed     Abstract available
    
    
    
76. HSU YC, Kuo CY, Chien MN, Jhuang JY, et al
    Overexpression of NR1D1 portends disease recurrence in thyroid cancer.
    J Clin Endocrinol Metab. 2024 Oct 3:dgae687. doi: 10.1210.
    PubMed     Abstract available
    
    
    
77. MEHANNA H, Nankivell P, Boelaert K, Woolley R, et al
    Diagnostic performance of ultrasound vs. ultrasound-guided FNAc in thyroid nodules: data from the ElaTION trial.
    J Clin Endocrinol Metab. 2024 Oct 3:dgae682. doi: 10.1210.
    PubMed     Abstract available
    
    
    
78. ROTONDI M, Endo M, Teliti M, Crescenzi A, et al
    Beyond malignancy risk stratification: FNAC report anticipates thyroid cancer staging. Insights from recent studies.
    J Clin Endocrinol Metab. 2024 Oct 1:dgae675. doi: 10.1210.
    PubMed     Abstract available
    
    
    September 2024
79. MORETTI S, Mandarano M, Menicali E, Guzzetti M, et al
    Wnt/B-catenin activation and TP53 mutations associate with distinct immune profiles in advanced thyroid cancer.
    J Clin Endocrinol Metab. 2024 Sep 27:dgae667. doi: 10.1210.
    PubMed     Abstract available
    
    
    
80. XU B, Baine MK, Jungbluth A, Alabkaa A, et al
    Detection of SEZ6, a therapeutic target, in medullary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Sep 26:dgae672. doi: 10.1210.
    PubMed     Abstract available
    
    
    
81. ZHANG Y, Zhang X, Lin L, Xing M, et al
    Efficacy and safety of targeted therapy for radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
    J Clin Endocrinol Metab. 2024 Sep 18:dgae617. doi: 10.1210.
    PubMed     Abstract available
    
    
    
82. MACIEL AAW, Danilovic DLS, Soares IC, Freitas TC, et al
    Association between papillary thyroid cancer and primary aldosteronism in individuals with hypertension.
    J Clin Endocrinol Metab. 2024 Sep 18:dgae653. doi: 10.1210.
    PubMed     Abstract available
    
    
    August 2024
83. YUAN J, Chen Z, Zhang J, Chen X, et al
    Preoperative Serum Lipids as Novel Predictors of Survival in 3575 Papillary Thyroid Cancer Patients.
    J Clin Endocrinol Metab. 2024 Aug 30:dgae601. doi: 10.1210.
    PubMed     Abstract available
    
    
    
84. MOOIJ CF, Zwaveling-Soonawala N, Hillebrand JJ, van Trotsenburg ASP, et al
    Approach to the Patient: Challenging Cases of Pediatric Thyrotoxicosis.
    J Clin Endocrinol Metab. 2024 Aug 27:dgae592. doi: 10.1210.
    PubMed     Abstract available
    
    
    
85. RAMONE T, Ghirri A, Prete A, Matrone A, et al
    Molecular profiling of low-risk papillary thyroid carcinoma (mPTC) on active surveillance.
    J Clin Endocrinol Metab. 2024 Aug 24:dgae575. doi: 10.1210.
    PubMed     Abstract available
    
    
    
86. XU Y, Gao J, Wang N, Zedenius J, et al
    BRAF-induced EHF expression affects TERT in aggressive papillary thyroid cancer.
    J Clin Endocrinol Metab. 2024 Aug 24:dgae589. doi: 10.1210.
    PubMed     Abstract available
    
    
    
87. STEGENGA MT, Oudijk L, van Velsen EFS, Peeters RP, et al
    Impact of Reclassification of Oncocytic and Follicular Thyroid Carcinoma by the 2022 WHO Classification.
    J Clin Endocrinol Metab. 2024 Aug 21:dgae581. doi: 10.1210.
    PubMed     Abstract available
    
    
    
88. CASTELLANOS LE, Zafereo ME, Sturgis EM, Wang JR, et al
    Pediatric Papillary Thyroid Carcinoma: Outcomes After Surgery Without Adjuvant Radioactive Iodine.
    J Clin Endocrinol Metab. 2024 Aug 20:dgae576. doi: 10.1210.
    PubMed     Abstract available
    
    
    
89. GRANI G, D'Elia S, Puxeddu E, Morelli S, et al
    Data-Driven Thyroglobulin Cutoffs for Low- and Intermediate-Risk Thyroid Cancer Follow-Up: ITCO Real-World Analysis.
    J Clin Endocrinol Metab. 2024 Aug 16:dgae559. doi: 10.1210.
    PubMed     Abstract available
    
    
    
90. IYER PC, Dadu R, Barque A, Zanelli C, et al
    Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay.
    J Clin Endocrinol Metab. 2024;109:2269-2273.
    PubMed     Abstract available
    
    
    
91. LI G, Ye Z, Wei T, Zhu J, et al
    Clinical Outcomes and Implications of Radioactive Iodine Therapy on Cancer-specific Survival in WHO Classification of FTC.
    J Clin Endocrinol Metab. 2024;109:2294-2305.
    PubMed     Abstract available
    
    
    
92. ENDO M, Peng J, Nabhan FA, Brock P, et al
    Indolent Behavior of Malignant Bethesda III Nodules Compared to Bethesda V/VI Nodules.
    J Clin Endocrinol Metab. 2024;109:2317-2324.
    PubMed     Abstract available
    
    
    
93. KONDA B, Sherman EJ, Massarelli E, Nieva J, et al
    Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2024 Aug 12:dgae512. doi: 10.1210.
    PubMed     Abstract available
    
    
    
94. GHOSH R, Auh S, Gubbi S, Veeraraghavan P, et al
    Association of Free Thyroxine with Progression-Free Survival in Intermediate and High Risk Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Aug 8:dgae537. doi: 10.1210.
    PubMed     Abstract available
    
    
    
95. WANG JR, Zafereo ME, Cabanillas ME, Wu CC, et al
    The association between thyroid differentiation score and survival outcomes in papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Aug 1:dgae532. doi: 10.1210.
    PubMed     Abstract available
    
    
    July 2024
96. FENG J, Wu C, Shen F, Cai W, et al
    Second Primary Differentiated Thyroid Carcinoma in Adult Cancer Survivors: A SEER Database Analysis.
    J Clin Endocrinol Metab. 2024 Jul 24:dgae501. doi: 10.1210.
    PubMed     Abstract available
    
    
    
97. WANG H, Li Q, Tian T, Liu B, et al
    Improving the Risk Prediction of the 2015 ATA Recurrence Risk Stratification in Papillary Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Jul 9:dgae465. doi: 10.1210.
    PubMed     Abstract available
    
    
    
98. JING R, Wu N, Wu Y, Zhang Q, et al
    Efficacy and safety of multikinase inhibitors for patients with refractory thyroid cancer: Systematic review and network meta-analysis.
    J Clin Endocrinol Metab. 2024 Jul 6:dgae454. doi: 10.1210.
    PubMed     Abstract available
    
    
    
99. 
    Correction to: "TERT Promoter Mutations Increase Tumor Aggressiveness by Altering TERT mRNA Splicing in Papillary Thyroid Carcinoma".
    J Clin Endocrinol Metab. 2024 Jul 1:dgae442. doi: 10.1210.
    PubMed    
    
    
    June 2024
100. SEHGAL K, Serritella A, Liu M, ONeill A, et al
     A phase I/II trial of sapanisertib in advanced anaplastic and radioiodine refractory differentiated thyroid carcinoma.
     J Clin Endocrinol Metab. 2024 Jun 29:dgae443. doi: 10.1210.
     PubMed     Abstract available
     
     
     
101. PARDI E, Poma AM, Torregrossa L, Pierotti L, et al
     Whole-exome sequencing of atypical parathyroid tumors detects novel and common genes linked to parathyroid tumorigenesis.
     J Clin Endocrinol Metab. 2024 Jun 28:dgae441. doi: 10.1210.
     PubMed     Abstract available
     
     
     
102. WILLIAMS MD, Liu Z, Rossi ED, Agarwal S, et al
     Seven years of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Rate of Acceptance and Variation of Diagnostic Approaches Across Different Continents.
     J Clin Endocrinol Metab. 2024 Jun 14:dgae354. doi: 10.1210.
     PubMed     Abstract available
     
     
     May 2024
103. CAO H, Shangguan L, Zhu H, Hu C, et al
     Prognostic analysis of 131I efficacy after papillary thyroid carcinoma surgery based on CT radiomics.
     J Clin Endocrinol Metab. 2024 May 27:dgae364. doi: 10.1210.
     PubMed     Abstract available
     
     
     
104. LEVESQUE F, Payne RJ, Beaudoin D, Boucher A, et al
     A Prospective Study of Publicly Funded Molecular Testing of Indeterminate Thyroid Nodules: Canada's Experience.
     J Clin Endocrinol Metab. 2024 May 23:dgae355. doi: 10.1210.
     PubMed     Abstract available
     
     
     
105. LI G, Chen W, Jiang K, Huang J, et al
     Exosome-mediated Delivery of miR-519e-5p Promotes Malignant Tumor Phenotype and CD8+ T-Cell Exhaustion in Metastatic PTC.
     J Clin Endocrinol Metab. 2024;109:1601-1617.
     PubMed     Abstract available
     
     
     
106. XIAN K, Xu S, Huang H, Xing C, et al
     Synergy of nodal factors in predicting recurrence after treatment of N1b papillary thyroid carcinoma.
     J Clin Endocrinol Metab. 2024 May 15:dgae329. doi: 10.1210.
     PubMed     Abstract available
     
     
     
107. ZHANG W, Lin S, Wang Z, Zhang W, et al
     Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targets in Thyroid Cancer.
     J Clin Endocrinol Metab. 2024 May 13:dgae327. doi: 10.1210.
     PubMed     Abstract available
     
     
     April 2024
108. PETROVIC I, LoPresti J, Fatemi S, Gianoukakis A, et al
     Influence of Thyroglobulin (Tg) Autoantibodies on Tg levels Measured by Different Methodologies: (IMA, LC-MS/MS and RIA).
     J Clin Endocrinol Metab. 2024 Apr 30:dgae286. doi: 10.1210.
     PubMed     Abstract available
     
     
     
109. SANT VR, Radhachandran A, Ivezic V, Lee DT, et al
     From Bench-to-Bedside: How Artificial Intelligence Is Changing Thyroid Nodule Diagnostics.
     J Clin Endocrinol Metab. 2024 Apr 29:dgae277. doi: 10.1210.
     PubMed     Abstract available
     
     
     
110. ABOU AZAR S, Tobias J, Applewhite M, Angelos P, et al
     Medullary Thyroid Cancer: Single Institute Experience over Three Decades and Risk Factors for Recurrence.
     J Clin Endocrinol Metab. 2024 Apr 23:dgae279. doi: 10.1210.
     PubMed     Abstract available
     
     
     
111. CHO YY, Ahn SH, Lee EK, Park YJ, et al
     Malignancy Risk of Follicular Neoplasm (Bethesda IV) With Variable Cutoffs of Tumor Size: A Systemic Review and Meta-Analysis.
     J Clin Endocrinol Metab. 2024;109:1383-1392.
     PubMed     Abstract available
     
     
     
112. TODA S, Hiroshima Y, Iwasaki H, Masudo K, et al
     Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan.
     J Clin Endocrinol Metab. 2024 Apr 17:dgae271. doi: 10.1210.
     PubMed     Abstract available
     
     
     
113. SAKO A, Matsuse M, Saenko V, Tanaka A, et al
     TERT promoter mutations increase tumor aggressiveness by altering TERT mRNA splicing in papillary thyroid carcinoma.
     J Clin Endocrinol Metab. 2024 Apr 5:dgae220. doi: 10.1210.
     PubMed     Abstract available
     
     
     
114. LIU CQ, Shen CK, Du YX, Li ZM, et al
     Survival outcome and optimal candidates of primary tumor resection for patients with metastatic medullary thyroid cancer.
     J Clin Endocrinol Metab. 2024 Apr 4:dgae214. doi: 10.1210.
     PubMed     Abstract available
     
     
     March 2024
115. LEE-SAXTON YJ, Egan CE, Bratton BA, Thiesmeyer JW, et al
     Low Mitotic Activity in Papillary Thyroid Cancer: A Marker for Aggressive Features and Recurrence.
     J Clin Endocrinol Metab. 2024 Mar 30:dgae203. doi: 10.1210.
     PubMed     Abstract available
     
     
     
116. MAROTTA V, Rocco D, Crocco A, Deiana MG, et al
     Survival predictors of radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the real-life.
     J Clin Endocrinol Metab. 2024 Mar 19:dgae181. doi: 10.1210.
     PubMed     Abstract available
     
     
     
117. OHIRA T, Nagao M, Hayashi F, Shimura H, et al
     Effects of Overweight on Risk of Thyroid Nodules in Children and Adolescents: The Fukushima Health Management Survey.
     J Clin Endocrinol Metab. 2024 Mar 13:dgae161. doi: 10.1210.
     PubMed     Abstract available
     
     
     
118. CHEN H, Liu Y, Wang F, Sun J, et al
     MeIS: DNA methylation-based immune response signatures for thyroid nodule diagnostics.
     J Clin Endocrinol Metab. 2024 Mar 7:dgae141. doi: 10.1210.
     PubMed     Abstract available
     
     
     
119. HENSLEY SG, Hu MI, Bassett RL, Ying AK, et al
     Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-term Outcomes in 144 Patients Over Six Decades.
     J Clin Endocrinol Metab. 2024 Mar 4:dgae133. doi: 10.1210.
     PubMed     Abstract available
     
     
     February 2024
120. JAGANNATH S, Mayilvaganan S
     Letter to the Editor from Jagannath and Mayilvaganan: "Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma".
     J Clin Endocrinol Metab. 2024 Feb 29:dgae117. doi: 10.1210.
     PubMed    
     
     
     
121. SARKAR R, Bolel P, Kapoor A, Eliseeva E, et al
     An Orally Efficacious Thyrotropin Receptor Ligand Inhibits Growth and Metastatic Activity of Thyroid Cancers.
     J Clin Endocrinol Metab. 2024 Feb 29:dgae114. doi: 10.1210.
     PubMed     Abstract available
     
     
     
122. SCHOLFIELD DW, Lopez J, Eagan A, Antal Z, et al
     Response to Letter to the Editor from Jagannath and Mayilvaganan: "Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma?".
     J Clin Endocrinol Metab. 2024 Feb 28:dgae118. doi: 10.1210.
     PubMed    
     
     
     
123. AHMADI S, Kotwal A, Bikas A, Xiang P, et al
     Outcomes of cytologically indeterminate thyroid nodules managed with Genomic Sequencing Classifier.
     J Clin Endocrinol Metab. 2024 Feb 28:dgae112. doi: 10.1210.
     PubMed     Abstract available
     
     
     
124. VAN DER TUIN K, Ruano D, Knijnenburg J, van der Luijt RB, et al
     Clinically-relevant Germline Variants in Children with Non-Medullary Thyroid Cancer.
     J Clin Endocrinol Metab. 2024 Feb 28:dgae107. doi: 10.1210.
     PubMed     Abstract available
     
     
     
125. MAINO F, Botte M, Dalmiglio C, Valerio L, et al
     Prognostic Factors Improving ATA Risk System and Dynamic Risk Stratification in Low- and Intermediate-Risk DTC Patients.
     J Clin Endocrinol Metab. 2024;109:722-729.
     PubMed     Abstract available
     
     
     
126. STEGENGA MT, van Velsen EFS, Oudijk L, Verburg FA, et al
     Clinical and Histopathological Risk Factors for Radioactive Iodine Refractory Follicular and Oncocytic Thyroid Carcinoma.
     J Clin Endocrinol Metab. 2024 Feb 13:dgae084. doi: 10.1210.
     PubMed     Abstract available
     
     
     
127. ALTSHULER B, Bikas A, Pappa T, Marqusee E, et al
     Non-Operative, Active Surveillance of Larger Malignant and Suspicious Thyroid Nodules.
     J Clin Endocrinol Metab. 2024 Feb 13:dgae082. doi: 10.1210.
     PubMed     Abstract available
     
     
     January 2024
128. CONDELLO V, Poma AM, Macerola E, Vignali P, et al
     Prevalence, Molecular Landscape and Clinical Impact of DICER1 and DGCR8 Mutated Follicular-Patterned Thyroid Nodules.
     J Clin Endocrinol Metab. 2024 Jan 22:dgae034. doi: 10.1210.
     PubMed     Abstract available
     
     
     
129. BHARADWAJ MS, Ballal S, Bal C
     Optimal Cumulative I-131 Activity in Metastatic Differentiated Thyroid Cancer: Balancing Efficacy and Adverse Events.
     J Clin Endocrinol Metab. 2024 Jan 12:dgae024. doi: 10.1210.
     PubMed     Abstract available
     
     
     
130. BUCZYNSKA A, Kosciuszko M, Sidorkiewicz I, Wiatr AA, et al
     Enhancing Angioinvasion Assessment in Papillary Thyroid Cancer via a Biomarker Panel Involving TAC, 8-OHdG and Sortilin.
     J Clin Endocrinol Metab. 2024 Jan 5:dgae007. doi: 10.1210.
     PubMed     Abstract available
     
     
     December 2023
131. KIM BH, Ryu SR, Lee JW, Song CM, et al
     Longitudinal changes in quality of life before and after thyroidectomy in patients with differentiated thyroid cancer.
     J Clin Endocrinol Metab. 2023 Dec 23:dgad748. doi: 10.1210.
     PubMed     Abstract available
     
     
     
132. PAPARODIS R, Livadas S, Karvounis E, Bantouna D, et al
     Elevated Preoperative TPO Ab Titers Decrease Risk for DTC in a Linear Fashion: A Retrospective Analysis of 1635 Cases.
     J Clin Endocrinol Metab. 2023;109:e347-e355.
     PubMed     Abstract available
     
     
     
133. GOLDNER W
     The Role of Age in the Risk Assessment of Differentiated Thyroid Cancers.
     J Clin Endocrinol Metab. 2023 Dec 20:dgad743. doi: 10.1210.
     PubMed    
     
     
     
134. LIN S, Wang Z, Xing M
     Association between a History of Breast Cancer and Decreased Thyroid Cancer-specific Mortality.
     J Clin Endocrinol Metab. 2023 Dec 8:dgad722. doi: 10.1210.
     PubMed     Abstract available
     
     
     
135. MU Z, Zhang X, Sun D, Sun Y, et al
     Characterizing genetic alterations related to radioiodine avidity in metastatic thyroid cancer.
     J Clin Endocrinol Metab. 2023 Dec 7:dgad697. doi: 10.1210.
     PubMed     Abstract available
     
     
     
136. LEUNG AM, Brent GA
     Pregnancy - Does Promotion of Growth Extend to Thyroid Cancer?
     J Clin Endocrinol Metab. 2023 Dec 2:dgad707. doi: 10.1210.
     PubMed    
     
     
     
137. WANG Y, Zou B, Zhang Y, Zhang J, et al
     Comprehensive long-read sequencing analysis discloses the transcriptome features of Papillary Thyroid Microcarcinoma.
     J Clin Endocrinol Metab. 2023 Dec 1:dgad695. doi: 10.1210.
     PubMed     Abstract available
     
     
     November 2023
138. YAMAZAKI H, Sugino K, Katoh R, Matsuzu K, et al
     Role of the degree of vascular invasion in predicting prognosis of follicular thyroid carcinoma.
     J Clin Endocrinol Metab. 2023 Nov 25:dgad689. doi: 10.1210.
     PubMed     Abstract available
     
     
     
139. TORA R, Welch J, Sun J, Agarwal SK, et al
     Phenotypic Profiling and Molecular Mechanisms in Hyperparathyroidism-jaw Tumor Syndrome.
     J Clin Endocrinol Metab. 2023;108:3165-3177.
     PubMed     Abstract available
     
     
     
140. LIU Q, Mao L, Zhang Z, Li G, et al
     Diagnostic Efficacy of FNA-Tg in DTC Cervical LN Metastasis and its Impact Factors: A Large Retrospective Study.
     J Clin Endocrinol Metab. 2023;108:3311-3319.
     PubMed     Abstract available
     
     
     
141. FALCHETTI A
     New Perspective on the Genetic Dissection Underlying the Development of Parathyroid Cancer.
     J Clin Endocrinol Metab. 2023;108:e1751-e1752.
     PubMed    
     
     
     
142. LI P, Liu Y, Wei T, Wang X, et al
     Effect and interactions of BRAF on lymph node metastasis in papillary thyroid carcinoma with Hashimoto's thyroiditis.
     J Clin Endocrinol Metab. 2023 Nov 15:dgad667. doi: 10.1210.
     PubMed     Abstract available
     
     
     October 2023
143. KWON H, Han KD, Moon SJ, Park SE, et al
     Nonalcoholic Fatty Liver Disease and the Risk of Thyroid Cancer Among Young Adults in South Korea.
     J Clin Endocrinol Metab. 2023 Oct 31:dgad575. doi: 10.1210.
     PubMed     Abstract available
     
     
     
144. DAI P, Zhao W, Zheng X, Luo H, et al
     Effect of radioactive iodine therapy on cancer-specific survival of papillary thyroid cancer tall cell variant.
     J Clin Endocrinol Metab. 2023 Oct 7:dgad580. doi: 10.1210.
     PubMed     Abstract available
     
     
     
145. 
     Correction to "The Outcomes of First Reoperation for Locoregionally Recurrent/Persistent Papillary Thyroid Carcinoma in Patients Who Initially Underwent Total Thyroidectomy and Remnant Ablation".
     J Clin Endocrinol Metab. 2023 Oct 3:dgad573. doi: 10.1210.
     PubMed    
     
     
     September 2023
146. PALYGA I, Rumian M, Kosel A, Albrzykowski M, et al
     The frequency of differentiated thyroid cancer recurrence in 2302 patients with excellent response to primary therapy.
     J Clin Endocrinol Metab. 2023 Sep 28:dgad571. doi: 10.1210.
     PubMed     Abstract available
     
     
     
147. XIAO WC, Li X, Shan R, Mei F, et al
     Pregnancy and progression of differentiated thyroid cancer: A propensity score-matched retrospective cohort study.
     J Clin Endocrinol Metab. 2023 Sep 20:dgad557. doi: 10.1210.
     PubMed     Abstract available
     
     
     
148. POZDEYEV N, Dighe M, Barrio M, Raeburn C, et al
     Thyroid cancer polygenic risk score improves classification of thyroid nodules as benign or malignant.
     J Clin Endocrinol Metab. 2023 Sep 8:dgad530. doi: 10.1210.
     PubMed     Abstract available
     
     
     
149. ILGAN S, Aydogan BI, Emer O, Anil C, et al
     Sonographic features of atypical and initially missed parathyroid adenomas: Lessons learned from a single center cohort.
     J Clin Endocrinol Metab. 2023 Sep 5:dgad527. doi: 10.1210.
     PubMed     Abstract available
     
     
     August 2023
150. GILLIS A, Chen H, Wang TS, Dream S, et al
     Racial and Ethnic Disparities in the Diagnosis and Treatment of Thyroid Disease: a Mini- Review.
     J Clin Endocrinol Metab. 2023 Aug 30:dgad519. doi: 10.1210.
     PubMed     Abstract available
     
     
     
151. HA EJ, Lee JH, Lee DH, Moon J, et al
     Artificial Intelligence Model Assisting Thyroid Nodule Diagnosis and Management: A Multicenter Diagnostic Study.
     J Clin Endocrinol Metab. 2023 Aug 25:dgad503. doi: 10.1210.
     PubMed     Abstract available
     
     
     
152. JU G, Sun Y, Wang H, Zhang X, et al
     Fusion oncogenes in patients with locally advanced or distant metastatic differentiated thyroid cancer.
     J Clin Endocrinol Metab. 2023 Aug 25:dgad500. doi: 10.1210.
     PubMed     Abstract available
     
     
     
153. LI H, Han R, Meng L, Sun Y, et al
     Nodal Metastases Associated with Fusion Oncogenes Are Age Dependent in Young Adult Patients with Thyroid Cancer.
     J Clin Endocrinol Metab. 2023 Aug 3:dgad458. doi: 10.1210.
     PubMed     Abstract available
     
     
     July 2023
154. MERCADO M
     The Role of Androgen Receptors in Thyroid Cancer Biology: Beyond Sexual Dimorphism.
     J Clin Endocrinol Metab. 2023 Jul 15:dgad424. doi: 10.1210.
     PubMed    
     
     
     
155. NOEL JE, Sinclair CF
     Radiofrequency Ablation for Benign Thyroid Nodules.
     J Clin Endocrinol Metab. 2023 Jul 4:dgad357. doi: 10.1210.
     PubMed     Abstract available
     
     
     June 2023
156. YAN L, Zhen Y, Li Y, Li X, et al
     Five-year Outcome Between Radiofrequency Ablation vs. Surgery for Unilateral Multifocal Papillary Thyroid Microcarcinoma.
     J Clin Endocrinol Metab. 2023 Jun 15:dgad360. doi: 10.1210.
     PubMed     Abstract available
     
     
     
157. YEH MW
     The molecular landscape of thyroid nodules: Diagnostic and prognostic revelations from a large multicenter cohort.
     J Clin Endocrinol Metab. 2023 Jun 15:dgad362. doi: 10.1210.
     PubMed    
     
     
     
158. SATAPATHY S, Majeed AK, Ballal S, Bal C, et al
     Differentiated thyroid cancers in young adults versus children: Clinical characteristics and ten-year follow-up outcomes.
     J Clin Endocrinol Metab. 2023 Jun 7:dgad343. doi: 10.1210.
     PubMed     Abstract available
     
     
     
159. ZHOU Y, Wang Y, Zhang Z, Yin X, et al
     Male sex is not a risk factor for prognosis in postoperative thyroid cancer patients: a propensity score matching study.
     J Clin Endocrinol Metab. 2023 Jun 2:dgad314. doi: 10.1210.
     PubMed     Abstract available
     
     
     
160. BOJARSKY M, Baran JA, Halada S, Isaza A, et al
     Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated with Radioactive Iodine Therapy.
     J Clin Endocrinol Metab. 2023 Jun 2:dgad322. doi: 10.1210.
     PubMed     Abstract available
     
     
     May 2023
161. LIN Y, Wu ZR, Shi YP, Ding M, et al
     Radiofrequency Ablation of Unifocal Papillary Thyroid Microcarcinoma With BRAF V600E Mutation.
     J Clin Endocrinol Metab. 2023 May 23:dgad269. doi: 10.1210.
     PubMed     Abstract available
     
     
     
162. CHOU CK, Chi SY, Hung YY, Yang YC, et al
     Clinical impact of androgen receptor-suppressing miR-146b expression in papillary thyroid cancer aggressiveness.
     J Clin Endocrinol Metab. 2023 May 23:dgad279. doi: 10.1210.
     PubMed     Abstract available
     
     
     
163. ALZAHRANI AS
     Clinical use of molecular data in thyroid nodules and cancer.
     J Clin Endocrinol Metab. 2023 May 18:dgad282. doi: 10.1210.
     PubMed     Abstract available
     
     
     
164. SUN Y, Sun Q, Tian J, He X, et al
     Impact of waiting time for radioactive iodine therapy on outcome in N1 stage papillary thyroid cancer.
     J Clin Endocrinol Metab. 2023 May 11:dgad264. doi: 10.1210.
     PubMed     Abstract available
     
     
     April 2023
165. ULLMANN TM, Sosa JA
     Delay in Surgery for Papillary Thyroid Cancer: A Proxy for Lower-Quality Care?
     J Clin Endocrinol Metab. 2023 Apr 21:dgad232. doi: 10.1210.
     PubMed    
     
     
     
166. CHIOSEA S, Hodak SP, Yip L, Abraham D, et al
     Molecular Profiling of 50,734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.
     J Clin Endocrinol Metab. 2023 Apr 18:dgad220. doi: 10.1210.
     PubMed     Abstract available
     
     
     March 2023
167. ALZAHRANI AS
     The risk of expanding risk stratification in thyroid cancer.
     J Clin Endocrinol Metab. 2023 Mar 29:dgad182. doi: 10.1210.
     PubMed    
     
     
     
168. CHAVES N, Broekhuis JM, Fligor SC, Collins RA, et al
     Delay in Surgery and Papillary Thyroid Cancer Survival in the United States: a SEER-Medicare Analysis.
     J Clin Endocrinol Metab. 2023 Mar 29:dgad163. doi: 10.1210.
     PubMed     Abstract available
     
     
     
169. VAN VELSEN EFS, Verburg FA
     Adjuvant Radioiodine for Intermediate-Risk Papillary Thyroid Cancer - To Treat or Not To Treat.
     J Clin Endocrinol Metab. 2023 Mar 25:dgad171. doi: 10.1210.
     PubMed    
     
     
     
170. KESBY N, Mechera R, Fuchs T, Papachristos A, et al
     Natural History and Predictive Factors of Outcome in Medullary Thyroid Microcarcinoma.
     J Clin Endocrinol Metab. 2023 Mar 25:dgad173. doi: 10.1210.
     PubMed     Abstract available
     
     
     
171. NASR CE
     Can one predict long-term growth of cytologically-benign thyroid nodules?
     J Clin Endocrinol Metab. 2023 Mar 22:dgad160. doi: 10.1210.
     PubMed    
     
     
     
172. JHA S, Welch J, Tora R, Lack J, et al
     Germline and somatic inactivating FLCN variants in parathyroid cancer and atypical parathyroid tumors.
     J Clin Endocrinol Metab. 2023 Mar 20:dgad136. doi: 10.1210.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum